Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects
| Autor: | Andrew Brugger, James E. Kipp, Pavlos Papadopoulos, John Ning, Barrett E. Rabinow, Joseph Chung Tak Wong, Atul Khare, Mahesh Chaubal |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Drug
media_common.quotation_subject Drug Evaluation Preclinical Biological Availability Pharmaceutical Science Pharmacology Dosage form chemistry.chemical_compound Drug Delivery Systems Suspensions Animals Humans Medicine media_common Clinical Trials as Topic business.industry IV injection Bioavailability Clinical trial Pharmaceutical Preparations Solubility Paclitaxel chemistry Injections Intravenous Nanoparticles Enhanced dissolution business Biological availability |
| Zdroj: | Advanced Drug Delivery Reviews. 60:939-954 |
| ISSN: | 0169-409X |
| DOI: | 10.1016/j.addr.2007.11.008 |
| Popis: | There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased research and development activities for intravenous suspensions. The first intravenously administered nanoparticulate product, Abraxane® (a reformulation of paclitaxel), was approved by the FDA in 2006. Additional clinical trials have been conducted or are ongoing for multiple other indications such as oncology, infective diseases, and restenosis. This article reviews various challenges associated with developing intravenous nanosuspension dosage forms. In addition, various formulation considerations specific to intravenous nanosuspensions as well as reported findings from various clinical studies have been discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect